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Abstract
Background: Terminal illness can cause a financial burden for many households. In England and Wales, fast-track
access to welfare payments is available through special rules for the terminally ill (SRTI). Individuals are eligible for
SRTI if they are judged to have 6 months or less to live. This criterion has been criticised as lacking a clinical basis,
and being unfair for people with conditions where life-expectancy is difficult to accurately assess.
Aim: To conduct a budget impact analysis on the possible increase in expenditure of personal independence
payments (PIP) following a change in England and Wales to SRTI so that everyone with a terminal illness is eligible.
Methods: The fraction of individuals with a given long-term condition was estimated by combining data from the
Health Survey for England, the Office for National Statistics (ONS) and the Department for Work and Pensions.
Logistic growth modelling and ONS population projections were used to project PIP expenditure from 2020 to
2025. The increased expenditure was calculated for hypothetical scenarios which may occur following an SRTI
regime change, specifically an increase of 1, 2 and 3 percentage points in the fraction of individuals claiming PIP
under SRTI. Data from the literature on the projected prevalence of mild, moderate and severe dementia was used
to calculate the cost if everyone with a given severity of dementia claimed PIP under SRTI.
Results: Under the current SRTI regime, PIP expenditure under SRTI was projected to increase from £0.231bn in
2020 to £0.260bn in 2025, compared to equivalent figures of £11.1bn and £12.7bn under non-SRTI. Expenditure in
2025 following an increase in the fraction claiming of 1, 2 and 3 percentage points was projected to be £1.1bn,
£1.9bn and £2.7bn respectively. In 2025, PIP expenditure was estimated to be £7.4bn if everyone with dementia
claimed under SRTI, compared to £6.4bn if only individuals with moderate and severe dementia claimed, and
£4.7bn if only individuals with severe dementia claimed.
Conclusion: Changes in SRTI are projected to lead to increases in PIP expenditure. However, the increased cost is
small compared to expenditure under non-SRTI, especially as the highest costs were associated with extreme
scenarios.
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Background
Terminal illness presents a financial challenge to many
households across the UK. Illness may increase house-
hold expenses directly with the costs of travel and medi-
cines, or indirectly by limiting the amount of paid work
that can be done by a patient or by their family carer
[1–3]. The total cost of living with a terminal illness in
the UK has been estimated to be between £12,000 and
£16,000 per year, with up to 60% of people living with
terminal illness dependent on benefits as their main
source of income [4]. Families who are socio-
economically disadvantaged are often worst hit and can
spend large fractions of their income on the added costs
brought on by terminal illness, leading to savings being
depleted [4]. Financial difficulties in terminal illness have
been linked to various negative outcomes for the person
with the illness as well as their caregivers and family
members. These negative outcomes can include worse
mental and physical health, difficulties with coping and
family conflict, poor bereavement outcomes and ongoing
debt [2, 5, 6].
Whilst financial support does exist in many countries,
patients and their carers report difficulties understanding
eligibility for benefits and navigating complex applica-
tion systems whilst juggling the demands of illness, on-
going treatments and caregiving [5, 7].. A study on ter-
minal lung cancer patients’ perceptions of claiming state
benefits in the UK reported that many people did not
know that they could claim financial benefits and found
claim forms complicated. Some people had to ‘struggle’
to obtain much-needed benefits to which they were enti-
tled, and many were shocked by how hard it was to ob-
tain the information needed to make claims [8]. Many
benefits to which patients are entitled go unclaimed [9].
Research has also identified financial hardship and a
need for more financial help for patients with other life
limiting conditions such as heart failure and chronic ob-
structive pulmonary disease (COPD) [10, 11], where an
unpredictable and prolonged disease trajectory can ex-
acerbate financial burden at the end of life.
Currently, people who are terminally ill in England and
Wales can have their application for certain benefits fast
tracked under the Special Rules for Terminal Illness
(SRTI) scheme. The SRTI scheme means that where there
is a ‘reasonable expectation of death within 6 months’ a
person can have their benefit claim fast tracked and will
automatically receive the higher benefit rate (https://www.
gov.uk/terminal-illness-benefits). However, the 6 months
eligibility rule is problematic, as many people with ter-
minal conditions have unpredictable disease trajectories,
where it is difficult to know at what point someone is
within 6 months of death. This applies to many different
conditions including cancer, but is a particular issue for
people with non-cancer conditions where accurate
prognostication is notoriously difficult [4, 12]. This in-
cludes motor neurone disease (MND), COPD, heart fail-
ure, stroke, dementia and many other conditions. The
uncertainty around disease trajectories makes clinicians
reluctant to confirm the eligibility of people with these
conditions for the SRTI scheme [13]. The administrative
burden and time delay in applying under non-SRTI means
many people will die without receiving any benefits.
In 2020, a change in the SRTI scheme will come into
effect in Scotland, with the 6 months eligibility criteria
replaced by a clinician’s judgement that an individual
has a progressive disease that can reasonably be ex-
pected to cause death [14]. There are campaigns for
similar changes to be enacted in England and Wales
[13], which have led to the government in England an-
nouncing a review of the benefits system for terminally
ill people. Such changes may lead to more people claim-
ing, both due to increased eligibility as well as greater
ease of demonstrating eligibility for people with unpre-
dictable disease categories. Some people may also claim
for longer due to accessing funds earlier than they would
have otherwise. One important question is the potential
increase in public expenditure caused by a change to the
SRTI eligibility criteria, as too great a cost would make
such a policy change unattractive.
This article attempts to inform policy by projecting
the scale of, and possible increase in, public expenditure
in England and Wales on one particular benefit follow-
ing a change to the SRTI scheme. In addition, a case
study was conducted in the area of dementia. As demen-
tia is rapidly growing in prevalence [15], a policy con-
cern is that changing the SRTI regime may result in a
large number of people with dementia being eligible for
many years. The case study examined the maximum
possible expenditure if all people with mild, moderate
and severe dementia claimed under SRTI.
The SRTI scheme applies to a range of benefits includ-
ing Personal Independence Payment (PIP), Disability
Living Allowance (DLA), Attendance Allowance (AA),
Employment Support Allowance (ESA) and Universal
Credit (UC) .A detailed analysis of all benefits included
in the SRTI scheme is beyond the scope of this paper.
Thus we chose to focus only on PIP. One reason for this
is that the available data on PIP claims made predictions
easier to estimate compared to other benefits (see the
discussion for more details). Expenditure on PIP is also
larger than most other benefits covered by SRTI, with
payments in England and Wales totalling £9.5 million in
2018/19, compared to £7.2 billion for DL, £5.2 billion
for AA, and £7.3 billion for UC. Only ESA had greater
expenditure, at £13.3 billion.1 The reader should bear in
1https://www.gov.uk/government/publications/benefit-expenditure-
and-caseload-tables-2019, accessed 03/02/21
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mind that our results should be seen in the context of
PIP being one part of a wider landscape of available
benefits.
Methods
PIP is a welfare benefit which aims to help people with
long-term conditions with their cost of living. It has two
components, mobility and daily living, each of which can
be paid at a standard or enhanced rate. In 2020, the
standard and enhanced rates were £23.60 and £62.25 per
week respectively for mobility and £59.70 and £89.15 per
week respectively for daily living. Eligibility is based pri-
marily on a condition’s practical effect on an individual’s
life. Individuals must also be aged 16 or over and either
be under State Pension age or to have been claiming
prior to reaching State Pension age. There are no eligi-
bility requirements based on income, assets or employ-
ment data. PIP was introduced as a replacement to
disability living allowance in 2013 with a gradual rollout.
As of 2019, around 3.1 million people receive PIP, of
which around 50,000 claim under SRTI.2
Expenditure was calculated in the following way: The
number of people in England and Wales with a given
condition was estimated. We then estimated the fraction
of people with a given condition claiming personal inde-
pendence payments (PIP) under SRTI and normal rules
(referred to hereafter as non-SRTI). Modelling was used
to project how these fractions will change in the future,
under ‘new rules’ for SRTI. This was combined with
population projections to estimate the number of people
claiming PIP, and hence the expected cost. To model al-
ternative scenarios, the parameters of the models were
changed to increase the fraction of individuals claiming
and/or claims’ growth rate.
A diagram illustrating the stages of analysis is given in
Fig. 1.
Data
Population estimates and projections
Midyear population estimates from 1995 to 2019 were ob-
tained from the Office for National Statistics (ONS) [16],
as were population projections from 2020 to 2025 [17].
Health survey for England
The Health Survey for England (HSE) is an annual large
scale survey which gathers data from several thousand
individuals about their lives and health. Data from the
surveys from 1995 until 2018, the latest year available at
the time of performing the analysis, were included [18–
42]. In each survey, data was collected on whether indi-
viduals had a long-term condition, categorised according
to the International Statistical Classification of Diseases
and Related Health Problems, 10th edition (ICD-10) [43]
at chapter level. ICD-10 chapter-level categories, includ-
ing examples of conditions for each category, are given
in Table 1.
Welfare claims
Data on the number and type of welfare claims was ob-
tained from the Department for Work and Pensions’
(DWP) Stat-Xplore service.3 The PIP Cases with Entitle-
ment dataset was used to extract the number of claims
per month in England and Wales from April 2013, the
first available time point, until January 2020. Claims
were broken down by the rules under which they were
made (non-SRTI/SRTI), type and levels of award, gen-
der, age and disability categorised by chapter-level ICD-
10 code.
Payment levels for each benefit were found from the
DWP website.4 Payments increase in line with inflation,
so that the current value of future payments in 2020
pounds will remain the same in future. This means that
all results are expressed in 2020 prices.
Welfare expenditure
The Stat-Xplore dataset DWP Expenditure was used to
obtain the total expenditure on PIP in each financial
year from 2013/14 to 2018/19.
Case study: dementia
Data on the current and projected prevalence of demen-
tia in England and Wales stratified by severity was ob-
tained from Wittenberg et al. [15].
Analysis
All analysis was performed in R.
Disease prevalence
The probability of an HSE respondent i having a given
condition was estimated using a series of logit models of
the form










where pi(condition) is the probability of i having the
given condition, ti is the year i completed the survey,
femalei is 1 if i is female and 0 otherwise, agei is a vector
of dummy variables indicating i ’s age in 5 year age
brackets, wi is the individual level HSE weight for i, the
βi s are parameters to be estimated and εi is an extreme
valued error term. Fitted values from the models were
used as estimates of disease prevalence at a given time
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has respondents from England only, and it was assumed
that disease prevalence in Wales would be the same as
for England. We discuss the impact of this assumption
on our results in section 4.
Number of people with long-term conditions
The results for disease prevalence were combined with
estimates of the mid-year populations of England and
Wales to produce yearly estimates of the number of
people with a given long-term condition. Monthly and
quarterly estimates were then interpolated using cubic
splines. Cubic spline interpolation was performed using
the Forsythe, Malcolm and Moler method [44], as imple-
mented in the spline function of the Stats package for R.
Fraction of individuals with a condition who are claimants
Combining estimates of the number of people with a
long-term condition with data on the number of welfare
(PIPS) claimants resulted in estimates of the fraction of
individuals with a given condition who claim a given
benefit at a given level, and whether under non-SRTI or
SRTI.5
Logistic growth models [45, 46] were then fitted to the
data on the fraction of individuals claiming benefits. Sep-
arate models were estimated for non-SRTI and SRTI, for
each level of each benefit, for each five-year age category
and for males and females, provided at least three pe-
riods with a positive number of claimants was observed.
The logistic growth models had the form
f t ¼
A
1þ e− rt−kð Þ þ εt :
Here ft is the fraction of individuals claiming at time t,
A is the long-run value of ft, which it approaches asymp-
totically, and r is the growth rate, with higher values of r
Fig. 1 Flow diagram illustrating analysis strategy
5For a small number of five-year age categories in the disease category
Certain infections and parasitic diseases, more people were observed to
claim than were estimated to exist in the population. Low absolute
numbers of people were involved, which led to the underestimation of
the disease prevalence. In these cases, the estimated population was as-
sumed to split evenly between claiming all levels of a given benefit.
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meaning that ft approaches A more quickly. k is a con-
stant and εt is an error term. Models were estimated
using non-linear least squares as implemented in the
Stats package for R. In some cases, models failed to con-











CA ¼ rt−k þ μt
Several models of this form were then estimated using




Þ as the dependent variable and a
range of values chosen for A. The final A was then
chosen as the one from the model with the highest R2.
The estimated parameters were used to project the
fraction of claimants from 2020 until 2025. In cases
where fewer than three periods had a positive number of
claimants, zero claimants were projected in future.
Hypothetical scenarios were constructed by choosing
alternative values for A and/or r. The alternative value of
the constant k was calculated using






where khyp, Ahyp and rhyp are the parameters for the
hypothetical scenario and T is the final period of estima-
tion and f estT is the estimated fraction claiming in T. This
ensures that in period T the fraction of individuals
claiming is identical for both the estimates based on
current rules and for the hypothetical scenario.
Current expenditure
Projections of fractions of individuals claiming, either
based on current rules or hypothetical scenarios under
‘new rules’ for SRTI were combined with the estimates
of the number of people with given conditions in order
to calculate the number of claimants, and from these ex-
penditure. Monthly results were converted to annual re-
sults to aid comprehension.
The estimated expenditure on PIP in each financial
year from 2013/14 to 2018/19 was compared to ob-
served expenditure. Projected expenditure was calibrated
by multiplying it by the average ratio of observed to esti-
mated expenditure.
Table 1 Chapter-level ICD-10 disease classifications
Code Description Example conditions
A00–B99 Certain infectious and parasitic diseases TB, polio, HIV, mumps
C00–D48 Neoplasms Cancers, benign tumours
D50–D89 Diseases of the blood and blood-forming organs and certain
disorders involving the immune mechanism
Anemia, Haemophillia
E00–E90 Endocrine, nutritional and metabolic diseases Diabetes, malnutrition, lactose intolerance
F00–F99 Mental and behavioural disorders Dementia due to Alzheimers, schizophrenia
G00–G99 Diseases of the nervous system Meningitis, MND, Parkinsons, Alzheimers
H00–H59 Diseases of the eye and adnexa Conjunctivitis, cataracts, glaucoma
H60–H95 Diseases of the ear and mastoid process Hearing loss
I00–I99 Diseases of the circulatory system Angina, heart disease, varicose veins
J00–J99 Diseases of the respiratory system Cold, sinitus, bronchitis
K00–K93 Diseases of the digestive system Caries, ulcers, coeliac disease
L00–L99 Diseases of the skin and subcutaneous tissue Impetigo, dermititis, psoriasis
M00–M99 Diseases of the musculoskeletal system and connective tissue Arthritis, sciatica, osteoporosis
N00–N99 Diseases of the genitourinary system Renal failure, urinary tract infections, infertility
O00–O99 Pregnancy, childbirth and the puerperium Ectopic pregnancy, long/obstructed labour
P00–P96 Certain conditions originating in the perinatal period Slow fetal growth, fetal blood loss
Q00–Q99 Congenital malformations, deformations and chromosomal abnormalities Microcephaly, cleft palate, Down syndrome
R00–R99 Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified Gangrene, nausea, vomiting, chronic pain
S00–T98 Injury, poisoning and certain other consequences of external causes Wounds, injuries, concussions
V01–Y98 External causes of morbidity and mortality Accidents, self-harm, assault
Z00–Z99 Factors influencing health status and contact with health services Examinations, vaccinations
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Hypothetical scenarios for claims under ‘new rules SRTI’
Three main scenarios were modelled: low, medium and
high increases in the number of individuals claiming
under ‘new rules’ SRTI. Various assumptions were com-
mon to each scenario about where increases would be
seen and how big they would be, largely guided by the
work of Etkind et al. [47]. Each scenario had the follow-
ing assumptions in common:-
1) Increases would be seen in disease categories
previously used by Etkind et al. [47] and others [48,
49] to estimate and project palliative care need.
These categories are: infectious and parasitic
diseases; neoplasms; mental and behavioural
disorders; diseases of the nervous system; diseases
of the circulatory system; diseases of the respiratory
system; diseases of the digestive system; and
diseases of the genitourinary system.
2) No increase in claims by individuals under the age
of 40. (on the basis of age related trends in palliative
care need) [47].
3) To reflect the requirement to have been claiming
PIP before the State Pension age, lower increases
were predicted among older age groups.
Specifically, increases for individuals aged 65–69
were assumed to be 75% of the increases for people
under 65, and increases for people aged over 70
were assumed to be 10% of the increases for people
under 65. These fractions were chosen to be similar
to the current fractions of individuals claiming aged
60–64 and 65 and over.
4) No change to the rate of increase of claims (i.e. r in
the logistic growth model equation.)
5) A total of 10% of new claimants would otherwise
have claimed under non-SRTI.
For the remaining disease and age categories, the fol-
lowing assumptions were made about the increase in the
long-run fraction of individuals claiming (i.e. A in the lo-
gistic growth model equation):-
1) Low scenario: an increase of 1 percentage point;
2) Medium scenario: an increase of 2 percentage
points;
3) High scenario: an increase of 3 percentage points.
These numbers were chosen as they lead to projected
numbers of claimants of similar orders of magnitude as
projections of numbers requiring palliative care. The as-
sumptions detailed above are summarised in Table 2.
Robustness tests
For each main scenario, several alternative scenarios
were modelled making alternative assumptions about
the growth rate of claims, age threshold for increased
claims and fraction of the individuals who otherwise
would have claimed under non-SRTI, as detailed in
Table 2.
Case study: dementia
Wittenberg et al. [28] provide projections of dementia
prevalence in England and Wales for each of the years
2019, 2020 and 2025. In each year, the numbers were
broken down by severity of dementia according to the
Mini-Mental State Examination score (mild dementia =
21–26; moderate dementia = 10–20; and severe demen-
tia = 0–10) [50]. Wittenberg et al.’s results were used to
create annual projections from 2019 to 2025 of the num-
ber of people with each level of dementia severity. This
was achieved using cubic spline interpolation, specifically
the Forsythe, Malcolm and Moler method [44] as imple-
mented in the spline function of the Stats package for R.
The prediction of the number of people were used to
calculate the maximum possible increase in PIP expend-
iture assuming that:-
1) Everyone with dementia claims;
2) Only people with severe and moderate dementia
claim;
3) Only people with severe dementia claim.
As Wittenberg et al’s results do not provide a break-
down of their figures by age, it is difficult to assess how
many people would be able to start claiming before the
State Pension age, as required by PIP rules. The aim of
the exercise was to estimate an upper limit to PIP ex-
penditure, and so we simply made the (unrealistic) as-
sumption that all individuals with a given severity of
dementia would be able to claim.
Results
Disease prevalence
Figure 2 illustrates the estimated prevalence of long-
term conditions over time classified using ICD-10. The
most common category was ‘Diseases of the musculo-
skeletal system and connective tissue’, with a little under
20% of the population estimated to have a condition.
Most categories were stable over time, but there were
upward trends for ‘Mental and behavioural disorders’
and ‘Endocrine, nutritional and metabolic diseases’.
Number of people with long-term conditions
Figure 3 illustrates the estimates of the number of
people with long-term conditions, accounting for a
growing and aging population, between 1995 and 2025.
There is an upward trend for most disease categories
due to the growing population, with the trends
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exaggerated for categories where the fraction of individ-
uals with a condition is also growing.
Fraction of individuals with a disease who are claimants
Table 3 lists the estimated maximum percentages of the
disease population claiming PIP for each disease cat-
egory. For many categories, very few claims (< 1%) were
seen, for example diseases of the blood, diseases of the
ear and diseases of the circulatory system. Several cat-
egories had a significant fraction of individuals claiming
under non-SRTI, for example diseases of the nervous
system with between 2 and 9% of individuals claiming
depending on the award and level. The greatest fraction
of claims was seen for mental and behavioural disorders,
where over 11% of individuals were estimated to claim
the daily living award at the standard rate.
For all disease categories, a small proportion of people
were estimated to claim under SRTI. The exception was
neoplasms, where approximately 1.6% of individuals
were estimated to claim both the daily living and
Table 2 Hypothetical scenarios under ‘new rules SRTI’





Low increase 1 pp 1 x current rate 40 10%
Medium increase 2 pp 1 x current rate 40 10%
High increase 3 pp 1 x current rate 40 10%
Robustness – varying growth rate
Low increase, fast growth 1 pp 5 x current rate 40 10%
Low increase, very fast growth 1 pp 10 x current rate 40 10%
Medium increase, fast growth 2 pp 5 x current rate 40 10%
Medium increase, very fast growth 2 pp 10 x current rate 40 10%
High increase, fast growth 3 pp 5 x current rate 40 10%
High increase, very fast growth 3 pp 10 x current rate 40 10%
Robustness – varying claims from non-SRTI
Low increase, low claims from non-SRTI 1 pp 1 x current rate 40 0%
Low increase, medium claims from non-SRTI 1 pp 1 x current rate 40 5%
Low increase, high claims from non-SRTI 1 pp 1 x current rate 40 20%
Medium increase, low claims from non-SRTI 2 pp 1 x current rate 40 0%
Medium increase, medium claims from non-SRTI 2 pp 1 x current rate 40 5%
Medium increase, high claims from non-SRTI 2 pp 1 x current rate 40 20%
High increase, low claims from non-SRTI 3 pp 1 x current rate 40 0%
High increase, medium claims from non-SRTI 3 pp 1 x current rate 40 5%
High increase, high claims from non-SRTI 3 pp 1 x current rate 40 20%
Robustness – varying age threshold for claim increase
Low increase, age 20 threshold 1 pp 1 x current rate 20 10%
Low increase, age 30 threshold 1 pp 1 x current rate 30 10%
Low increase, age 50 threshold 1 pp 1 x current rate 50 10%
Medium increase, age 20 threshold 2 pp 1 x current rate 20 10%
Medium increase, age 30 threshold 2 pp 1 x current rate 30 10%
Medium increase, age 50 threshold 2 pp 1 x current rate 50 10%
High increase, age 20 threshold 3 pp 1 x current rate 20 10%
High increase, age 30 threshold 3 pp 1 x current rate 30 10%
High increase, age 50 threshold 3 pp 1 x current rate 50 10%
Each scenario has the following assumptions in common:- (1) Increased SRTI claims were only seen in the disease categories infectious and parasitic diseases;
neoplasms; mental and behavioural disorders; diseases of the nervous system; diseases of the circulatory system; diseases of the respiratory system; diseases of
the digestive system; and diseases of the genitourinary system. (2) Long-run claim increases for 65–69 year olds and over 70s were 75 and 10% respectively of the
increases for individuals aged under 65
SRTI special rules for the terminally ill, pp percentage point(s)
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mobility awards. In all other disease categories less than
0.1% of people claimed under SRTI.
Splitting data on the fraction of claimants by disease, PIP
component, level, rules claimed under, age category and
gender resulted in 2340 sub-datasets. Of these, 596 had
fewer than three periods with a positive number of claims,
meaning zero claims were projected in those groups in fu-
ture. Logistic regression models were run on the remaining
1744 sub-datasets, and in 155 (8.0%) of cases failed to con-
verge The mean number of monthly claimants in the cases
where logistic growth models failed to converge was 9.7.
The mean residual standard error of converged logistic
growth models was 7.8 × 10− 4. Full model results are pro-
vided as supplementary online material.
Current expenditure
The average ratio of estimated PIP expenditure from
data on the number of claimants to actual expenditure
from published figures was 1.13. Predicted future ex-
penditure under the current SRTI regime and hypothet-
ical future SRTI regimes was calibrated by multiplying
by this ratio. Table 4 lists the estimated expenditure
Fig. 2 Estimated disease prevalence based on Health Survey for England
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Fig. 3 Estimated and projected number of people with long-term conditions
Table 3 Estimated long-term percentages of disease populations claiming PIP
Disease Percentage of disease population claiming
SRTI Non-SRTI













Certain Infectious and Parasitic Diseases (A00 - B99) 0.01 0.01 3.39 5.24 5.48 2.26
Neoplasms (C00 - D48) 1.64 1.63 1.49 1.84 1.74 0.89
Diseases of the Blood and Blood forming organs and certain
diseases involving the immune mechanism (D50 - D89
0 0 0.33 0.55 0.54 0.27
Endocrine, Nutritional and Metabolic Diseases (E00 - E90) 0 0 0.2 0.26 0.28 0.13
Mental and Behavioural Disorders (F00 - F99) 0.01 0.01 11.37 5.99 7.27 4.91
Diseases of the Nervous System (G00 - G99) 0.06 0.06 6.87 4 8.77 1.99
Diseases of the Eye and Adnexa (H00 - H59) 0 0 2.01 0.44 2.44 0.31
Diseases of the Ear and Mastoid Process (H60 - H95) 0 0 0.38 0.46 0.23 1.2
Diseases of the Circulatory System (I00 - I99) 0.01 0 0.19 0.43 0.34 0.24
Diseases of the Respiratory System (J00 - J99) 0.02 0.02 0.65 1.26 1.19 0.69
Diseases of the Digestive System (K00 - K93) 0.01 0.01 0.25 0.47 0.28 0.22
Diseases of the Skin and Subcutaneous System (L00 - L99) 0 0 0.22 0.42 0.37 0.2
Diseases of the Musculoskeletal system and Connective
Tissue (M00 - M99)
0.01 0.01 1.78 4.9 2.72 2.41
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each year under the current regime. Expenditure was
projected to increase over the period from 2020 to 2025
for both award types (daily living and mobility) under
both non-SRTI and SRTI. However, expenditure on
SRTI was considerably lower than for non-SRTI.
Hypothetical scenarios for claims under ‘new rules SRTI’
Figure 4 compares projected expenditure under the
current SRTI regime and under the three main scenarios
of low, medium and high increases in claims under a
new SRTI regime, with full numbers available in Table
of the online supplementary material. As expected, SRTI
expenditure was higher under the hypothetical scenarios
representing possible new SRTI regimes than projections
under the current regime, going from around £0.260
billion per year in the current regime to £1.1 billion per
year by 2025 in the low scenario, £1.9 billion pounds in
the medium scenario and £2.6 billion in the high sce-
nario. However, even in the high increase scenario, ex-
penditure under non-SRTI was still many times higher
than under SRTI.
Robustness tests
Figure 5a illustrates how robust the scenarios are to
varying the assumptions about the rate of increase of
SRTI claims, with full numbers available in Table of the
supplementary online material. It can be seen that if
claims grow to their new long-term levels at a rate either
five or 10 times the current estimated growth rate, ex-
penditure under SRTI increased. This effect was more
Table 4 Estimated future Personal Independence Payment expenditure under current SRTI regime
Rules Component Expenditure (£ millions)
2020 2021 2022 2023 2024 2025
Non-SRTI Daily Living Enhanced 4641 4822 4988 5143 5297 5455
Daily Living Standard 3261 3343 3413 3472 3526 3582
Mobility Enhanced 3154 3312 3427 3518 3598 3676
Mobility Standard 749 776 799 819 839 858
SRTI Daily Living Enhanced 137 141 144 148 151 154
Mobility Enhanced 94 97 99 102 104 106
Fig. 4 Past and predicted personal independence payment (PIP) expenditure, comparing the current SRTI scheme and the proposed new SRTI
scheme, under different scenarios for low, medium and high increases in claims




Fig. 5 Comparison of modelling scenarios with varying assumptions about a growth rate, b age thresholds for claim increases and c fraction of
increased claims from non-special rules for the terminally ill
Webb et al. BMC Health Services Research          (2021) 21:421 Page 11 of 15
pronounced for the high increase scenario. However, the
overall conclusion that expenditure under non-SRTI is
several times higher than SRTI expenditure remains
unchanged.
Figure 5b illustrates the impact of varying the age
threshold at which increases in SRTI claims occur, with
full numbers available as supplementary on-line mater-
ial. Some variation in expenditure was seen, however the
amount of variation was not as large as seen when vary-
ing the growth rate. Figure 5c shows the impact of vary-
ing the fraction of new SRTI claims which otherwise
would have been made under non-SRTI. Little variation
of non-SRTI expenditure was seen, indicating that any
cost offsets were probably small.
Case study: dementia
Table 5 lists the projected expenditure of all individuals
with varying severity of dementia claimed under SRTI.
The majority of expenditure was on individuals with se-
vere dementia, and there was an increasing trend in
expenditure.
Discussion
The overall finding from projecting several different sce-
narios is that, although SRTI expenditure will increase
following any change to eligibility, it will remain a frac-
tion of expenditure under non-SRTI. For example, even
in the high increase scenario, the projected cost of PIP
under SRTI of just over £2.5 billion in 2025 is still only
around a fifth of the projected cost under non-SRTI.
This conclusion appears to be robust to the assumptions
made about how quickly new SRTI claims will grow, the
age profile of new SRTI claimants and how many SRTI
claims would otherwise have been made under non-
SRTI.
To examine the plausibility of the hypothetical scenar-
ios, we can compare the number of PIP claims made
under each scenario to the number who are predicted to
require palliative care. This comparison is useful as it is
likely that the population eligible to claim under any fu-
ture SRTI scheme will overlap closely with the popula-
tion requiring palliative care.
Etkind et al. [47] estimated that the number of people
in England and Wales requiring palliative care will rise
from between 375,000 and 385,000 in 2020 to between
410,000 and 445,000 by 2030. By comparison, in the
high increase scenario, PIP claims under SRTI are pro-
jected to be over 600,000 by 2025. However, guidelines
in Scotland where a change in the SRTI regime has
already occurred state that to be eligible an individual’s
disease should typically be advanced, progressive, not
amenable to further curative treatment, and/or with
worsening symptoms despite optimal management.
Under any similar regime it seems unlikely that so many
people would be eligible for SRTI while not requiring
palliative care, indicating the high increase scenario rep-
resents an extreme case which is unlikely to occur in
reality.
Under the medium and low increase scenarios, the
number of people claiming under a new SRTI scheme is
projected by 2025 to reach 438,000 and 255,000, respect-
ively. Such numbers seem more plausible, and which
scenario is closer to reality may be determined by what
fraction of eligible people claim.
The modelling approach of assuming the long-run
fractions of individuals claiming remain stable over time
means the analysis is able to take account of demo-
graphic changes. Thus, for example, the number of
people with dementia is projected to rise as the number
of older people in the UK also rises. However, the ana-
lysis takes account of this by assuming that in the long
run the fraction of, for example, women aged 65–69
with dementia who claim PIP under SRTI will remain
stable.
Dementia is an important case study to examine, as it
is a common condition which is growing with the aging
population. In the case in which all people with demen-
tia claim under SRTI, the increased expenditure is large,
rising from £6.3 billion in 2020 to £7.4 billion in 2025.
However, the expenditure should still be seen in the
context of being only just over half the projected ex-
penditure under non-SRTI in 2025.
The dementia scenarios presented here should all be
regarded as extreme scenarios, and it is extremely im-
plausible that any would occur. For example, they would
either require all individuals to start claiming before the
State Pension age, or for the abolition of that rule, a re-
mote possibility given PIP’s function as an income-
replacement benefit. Even for people below the age
threshold, if any new SRTI regime had similar guidelines
to those in Scotland cited above, it seems unlikely that
even all people with severe dementia would be eligible,
meaning a maximum expenditure of £4.7 billion by
2025. In addition, it is unlikely that all those eligible
would in fact claim PIP, further reducing potential costs,
and it is implausible that there would be no cost offsets
in the form of reduced PIP claims under non-SRTI. Al-
though the scenarios are unrealistic, we believe they are
still useful to present in the light of policy concerns
Table 5 Maximum expenditure if individuals with varying
severity of dementia are eligible to claim under SRTI
Dementia severity Cost (£ billions)
2019 2020 2021 2022 2023 2024 2025
All 6.15 6.33 6.51 6.71 6.92 7.15 7.38
Moderate and severe 5.27 5.43 5.61 5.79 5.99 6.19 6.41
Severe only 3.57 3.8 4.01 4.2 4.37 4.53 4.68
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about potentially very large costs associated with demen-
tia [50–52].
Most PIP claims under SRTI were from people with
cancer, and very few SRTI claims were seen from any
other disease category. This confirms previous findings
which show that clinicians were reluctant to certify pa-
tients in disease areas other than cancer [13], and also that
the trajectory of terminal illness such as COPD or demen-
tia are much more difficult to predict than cancer [12].
The main implication of the current report for policy
is that whilst changes to the SRTI scheme will increase
expenditure on PIPS and other benefits, the cost impli-
cations will be small compared to the overall cost of PIP.
The affordability of any change is ultimately a political
question, however this research shows that it is unlikely
to lead to significant increases to PIP expenditure in per-
centage terms.
In this report a wide variety of possible scenarios were
modelled. It will be important in future research to com-
pare the changes in Scotland, where a new regime is
already in place, with the potential scenarios modelled
here for England and Wales.
The analysis has several limitations. It only examines
the potential impact of changes to SRTI on PIP, and does
not address other welfare payments eligible under the
SRTI scheme such as Attendance Allowance (AA), Em-
ployment Support Allowance (ESA) or Universal Credit
(UC). While a similar pattern of expenditure could be ex-
pected for other payments, the population claiming them
are not necessarily similar to people claiming PIP. For ex-
ample ESA, unlike PIP, is considered an in-work benefit,
and only people over 65 are eligible for AA.
It is a limitation of this study that its results may not
be generalizable to other benefits. However, a full ana-
lysis of the impact of an SRTI regime change on the
whole England and Wales benefit system was beyond
the scope of our research project, as we instead sought
to provide a detailed analysis of one welfare payment.
The reason for choosing PIP was the available data made
it more amenable to analyse than AA, ESA or UC. From
the available data, it is clear what rules individuals are
claiming under, unlike ESA. Individuals’ primary long-
term condition is categorised according to a widely used
system with PIP, making comparisons with other data-
sets on e.g. disease prevalence easier, unlike AA which
uses a system apparently unique to DWP statistics. PIP
data is also reported monthly, unlike AA and ESA which
is reported quarterly. Finally, there will inevitably be a
period of adjustment after any change of eligibility. As
PIP began in 2013 and the number of claims have grown
steadily since then, it is possible to use the data to esti-
mate the dynamics of an adjustment period. Further
work is necessary to analyse the full expenditure impact
of a new SRTI regime.
While the analysis controlled for disease category, the
available data only classified claims according to
chapter-level ICD-10 codes. There are very broad, for
example the category mental and behavioural disorders
includes dementia, where potentially a large number of
claims under SRTI could be made, as well as many non-
terminal conditions such as schizophrenia and learning
difficulties. In addition, disease prevalence was calculated
for both England and Wales using data only from
England. However, we do not expect this will have a
large impact on results. England and Wales have many
similarities, both being constituent parts of the United
Kingdom, and the relative population sizes (around 55
million for England compared to 3 million for Wales)
will tend to be dominated by those for England.
Due to the complexity of the calculations, confidence
intervals were not explicitly computed for any given sce-
nario. However, a range of scenarios were modelled, and
robustness tests were performed with several key vari-
ables in order to give greater confidence that the conclu-
sions were robust even to extreme situations in which
twice as many people were claiming PIP under SRTI as
were in need of palliative care.
This analysis only addresses the costs of any potential
change to SRTI. It does not attempt to quantify any eco-
nomic offsets or other benefits that may occur. The rela-
tionship between financial support and economic
outcomes is complex and there are various ways that im-
proved welfare provision can lead to economic benefits.
These benefits may include lower health care costs at
the end of life [53, 54]; decreased carer burden amongst
informal/family caregivers [55]; improved bereavement
outcomes for family carers [56, 57]; impacts on family
carer employment status and ability to continue in/re-
turn to the workforce [58, 59]; impacts on place of death
and achieving preferred place of death [54, 60].
Conclusion
A change to the SRTI scheme which expands eligibility
to any person with terminal illness will lead to increased
government expenditure on PIP, and this increase is
likely to be mirrored by similar increases in expenditure
on other eligible benefits. However, the cost implications
of a change to SRTI will be small compared to the over-
all cost of PIP. In the most plausible ‘low increase’ and
‘medium increase’ scenarios, the projected annual costs
of PIP claims under the new SRTI scheme are around
£1.1 billion and £1.9 billion respectively. This compares
to the projected cost of over £12 billion under non-
SRTI. There are several ways that changes could be im-
plemented, with varying consequences for eligibility and
uptake. However, a range of scenarios were modelled,
and the conclusions were robust even to extreme situa-
tions. Careful consideration should be given to how
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terminal illness is defined under any new SRTI scheme,
as this is likely to have significant implications for eligi-
bility and subsequently on expenditure. Finally, any in-
crease to the overall cost is likely to be offset, at least to
some extent, by wider economic benefits that are rea-
lised through improving financial support for people
with terminal illness.
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